Supplementary Data 1 from Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multicenter Basket Trial Analysis (NCI/SWOG S1609)
2026-06-17
Data from Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multicenter Basket Trial Analysis (NCI/SWOG S1609)
2026-06-17
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma
European Journal of Cancer · 2026-06-01
Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)–targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH).
Journal of Clinical Oncology · 2026-05-28
A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study.
Journal of Clinical Oncology · 2026-05-28
The impact of online CME on addressing clinical decision-making for immunotherapy in advanced squamous NSCLC.
Journal of Clinical Oncology · 2026-05-28
Risk factors for drug-induced pneumonitis from trastuzumab deruxtecan in patients with advanced HER2-positive solid malignancies.
Journal of Clinical Oncology · 2026-05-28
Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with <i>STK11</i> , <i>KEAP1</i> , and/or <i>KRAS</i> mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.
Journal of Clinical Oncology · 2026-05-28
DART (NCI/SWOG S1609): Comprehensive results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.
Journal of Clinical Oncology · 2026-05-27
Outcomes of patients with rare cancers treated with combination immune checkpoint inhibitors with and without lung and/or liver metastases (NCI/SWOG S1609).
Journal of Clinical Oncology · 2026-05-27
Safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activities of FL115, a novel IL-15 superagonist, from the first-in-human study in patients with locally advanced/metastatic solid tumors.
Journal of Clinical Oncology · 2026-05-27
microRNA-25 drives immune checkpoint therapy resistance by repressing innate and humoral immunity via Syndecan-3
Nature Communications · 2026-05-20
Molecular Translators as a Computational Primitive for Biomarker Discovery: Learnability Gains Under Conserved Information Ceilings
bioRxiv (Cold Spring Harbor Laboratory) · 2026-04-30
Abstract 7594: Combining electronic health records, environmental, and genomics data for lung cancer risk prediction in Southern California.
Cancer Research · 2026-04-03
Abstract 1591: microRNA-25 drives initial resistance to immune checkpoint therapy by repressing innate and humoral immunity via Syndecan3
Cancer Research · 2026-04-03
Abstract 5333: Profiling membrane antigen expression of select antibody-drug conjugate (ADC) targets in <i>EGFR</i> -altered non-small cell lung cancer treated with osimertinib.
Cancer Research · 2026-04-03
Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)
Cancer · 2026-03-27
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
Journal for ImmunoTherapy of Cancer · 2026-02-01 · 1 citations
Unlocking the potential of immunotherapy for patients with resectable non–small cell lung cancer
Frontiers in Oncology · 2026-01-12
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
Journal of Gynecologic Oncology · 2026-01-01